Cargando…

Roles of Ceramides in Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is one of the most common chronic liver diseases, ranging from simple steatosis to steatohepatitis, fibrosis, and cirrhosis. Its prevalence is rapidly increasing and presently affects around 25% of the general population of Western countries, due to the obesity epid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajduch, Eric, Lachkar, Floriane, Ferré, Pascal, Foufelle, Fabienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920467/ https://www.ncbi.nlm.nih.gov/pubmed/33669443 http://dx.doi.org/10.3390/jcm10040792

Ejemplares similares

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes
por: Carlier, Aurélie, et al.
Publicado: (2020)

Characterising the Inhibitory Actions of Ceramide upon Insulin Signaling in Different Skeletal Muscle Cell Models: A Mechanistic Insight
por: Mahfouz, Rana, et al.
Publicado: (2014)

Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
por: Simon, Jorge, et al.
Publicado: (2019)

Ceramide analog C2-cer induces a loss in insulin sensitivity in muscle cells through the salvage/recycling pathway
por: Bandet, Cécile L., et al.
Publicado: (2023)

Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans
por: Apostolopoulou, Maria, et al.
Publicado: (2020)

Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis
por: Kasumov, Takhar, et al.
Publicado: (2015)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2021)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease
por: Zhu, Cheng, et al.
Publicado: (2023)

Role of Leptin in Non-Alcoholic Fatty Liver Disease
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021)

The Role of Non-Alcoholic Fatty Liver Disease in Infections
por: Krznarić, Juraj, et al.
Publicado: (2022)

The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
por: Winarto, Jessica, et al.
Publicado: (2023)

Role of Hepatokines in Non-alcoholic Fatty Liver Disease
por: Ke, Yini, et al.
Publicado: (2019)

Plasma Membrane Subdomain Compartmentalization Contributes to Distinct Mechanisms of Ceramide Action on Insulin Signaling
por: Blouin, Cédric M., et al.
Publicado: (2010)

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update
por: Hliwa, Aleksandra, et al.
Publicado: (2021)

Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases
por: Park, Ji-Won, et al.
Publicado: (2021)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease
por: Li, Jiawei, et al.
Publicado: (2016)

Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease
por: Torres, Jorge-Luis, et al.
Publicado: (2018)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Role of endoplasmic reticulum stress in drug‐induced toxicity
por: Foufelle, Fabienne, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease
por: Perla, Francesco M., et al.
Publicado: (2017)

The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease
por: Engelmann, Cornelius, et al.
Publicado: (2022)

Expanding Pharmacists’ Role in the Management of Non-Alcoholic Fatty Liver Disease
por: Syed-Abdul, Majid Mufaqam
Publicado: (2023)

Pathology of non-alcoholic fatty liver disease
por: Cataldo, Ivana, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease in Children
por: Brecelj, Jernej, et al.
Publicado: (2021)

Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)

Pathogenesis of non-alcoholic fatty liver disease
por: Dowman, J. K., et al.
Publicado: (2010)

Non-Alcoholic Fatty Liver Disease in Children
por: SINGER, CRISTINA, et al.
Publicado: (2014)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Iron and non-alcoholic fatty liver disease
por: Britton, Laurence J, et al.
Publicado: (2016)

Apoptosis and non-alcoholic fatty liver diseases
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Lipidomics in non-alcoholic fatty liver disease
por: Kartsoli, Sofia, et al.
Publicado: (2020)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
por: Malnick, Stephen D. H., et al.
Publicado: (2022)

Evaluating causality of cellular senescence in non-alcoholic fatty liver disease
por: Meijnikman, Abraham Stijn, et al.
Publicado: (2021)

Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells
por: Bandet, Cécile L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m7ltee6b7dub3klhtmdaes68od